• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Medivation Gets OK; New Competitor for Provenge


Dendreon has another competitor for its drug Provenge to worry about now that the Food and Drug Administration has approved Medivation's late-stage prostate cancer treatment.

Updated as of Sept. 4.

Dendreon has another competitor for its drug Provenge to worry about now that the Food and Drug Administration (FDA) has approved Medivation’s late-stage prostate cancer treatment.

The drug, jointly developed by Medivation and Astellas Phama, is approved to treat men with prostate cancer that has spread or returned after prior treatment with docetaxel. The drug, brand name Xtandi, will be a direct competitor of Dendreon’s Provenge.

"The need for additional treatment options for advanced prostate cancer continues to be important for patients," Richard Pazdur, director of hematology and oncology products at the F.D.A.’s drug evaluation and research center, said in a statement. "Xtandi is the latest treatment for this disease to demonstrate its ability to extend a patient’s life."

Dendreon was down 1.3% for the day, while Medivation was up 1.41% until shares were halted just before the FDA announcement. When trading resumed, the finished out the day up 8%. On Monday at opening bell Medivation stock was up another 4.7% to $109.63, hitting a new 52-week high.

Trading was halted just after 1 p.m. on Friday when the FDA announced the approval and resumed around 3:40 p.m. On Monday, the stock was up 4% at the opening bell.

Medivation’s stock is up 110% on the year. Dendreon is down 39.95%. Dendreon’s Provenge was already struggling with lagging sales because of another competitor: Johnson & Johnson’s Zytiga. JNJ fell slightly at the news of the FDA’s approval, but was still up .22%.

In November, Medivation had reported that Xtandi improved median survival by 4.8 months in a study. The most common side effects with Xtandi were weakness, fatigue and back pain.

"We believe XTANDI has the potential to play an important role in the treatment of advanced prostate cancer," Stephen Eck, M.D., Ph.D., vice president of Medical Oncology, Astellas Pharma Global Development, said in a statement.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice